U.S. FDA Approves Guselkumab for Pediatric Psoriasis and Active PsA
The U.S. Food and Drug Administration (FDA) approved guselkumab (Tremfya) for the treatment of children six years and up who also weigh at least 40 kg with moderate-to-severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis (PsA).